Suppr超能文献

强度调制质子放射治疗作为中国鼻咽癌根治性治疗手段的成本效果分析。

Intensity-modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: Cost-effectiveness analysis.

机构信息

Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou, China.

Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.

出版信息

Head Neck. 2022 Feb;44(2):431-442. doi: 10.1002/hed.26941. Epub 2021 Nov 26.

Abstract

BACKGROUND

Compared to conventional intensity-modulated photon radiation therapy (IMRT), intensity-modulated proton radiation therapy (IMPT) has potential to reduce irradiation-induced late toxicities while maintaining excellent tumor control in patients with nasopharyngeal carcinoma (NPC). However, the relevant cost-effectiveness remains controversial.

METHODS

A Markov decision tree analysis was performed under the assumption that IMPT offered normal tissue complication probability reduction (NTCP reduction) in long-term dysphagia, xerostomia, and hearing loss, compared to IMRT. Base-case evaluation was performed on T2N2M0 NPC of median age (43 years old). A Chinese societal willingness-to-pay threshold (33558 US dollars [$])/quality-adjusted life-year [QALY]) was adopted.

RESULTS

For patients at median age and having NTCP reduction of 10%, 20%, 30%, 40%, 50%, and 60%, their incremental cost-effectiveness ratios were $102684.0/QALY, $43161.2/QALY, $24134.7/QALY, $13991.6/QALY, $8259.8/QALY, and $4436.1/QALY, respectively; IMPT should provide an NTCP reduction of ≥24% to be considered cost-effective.

CONCLUSIONS

IMPT has potential to be cost-effective for average Chinese NPC patients and should be validated clinically.

摘要

背景

与传统调强光子放射治疗(IMRT)相比,调强质子放射治疗(IMPT)有可能在保持鼻咽癌(NPC)患者优异肿瘤控制的同时,降低放疗引起的迟发性毒性。然而,其相关成本效益仍存在争议。

方法

假设与 IMRT 相比,IMPT 可降低长期吞咽困难、口干和听力损失的正常组织并发症概率(NTCP 降低),我们进行了马尔可夫决策树分析。基础情况评估基于 T2N2M0 期 NPC 患者的中位年龄(43 岁)。采用中国社会意愿支付阈值(33558 美元[美元] / 质量调整生命年[QALY])。

结果

对于中位年龄患者和 NTCP 降低 10%、20%、30%、40%、50%和 60%的患者,增量成本效益比分别为 102684.0 美元/QALY、43161.2 美元/QALY、24134.7 美元/QALY、13991.6 美元/QALY、8259.8 美元/QALY 和 4436.1 美元/QALY;IMPT 应提供 ≥24%的 NTCP 降低,才能被认为具有成本效益。

结论

对于普通中国 NPC 患者,IMPT 具有潜在的成本效益,应在临床上进行验证。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验